Skip to content
Active Currencies: 17,437
Market Cap: $2.376T
Bitcoin Dominance: 56.38%
24h Market Cap Change: $5.17

VitaDAO – Pfizer Ventures raise millions for research on extending human life
Written by Written by Saman Waris
Reviewed by Reviewed by Saman Waris
Updated January 31, 2023
  • VitaDAO has raised $4.1 million from Pfizer Ventures among other investors.
  • The latest fund raiser will fund longevity research projects and the development of its first biotech startup.

VitaDAO has raised $4.1 million from Pfizer Ventures among other investors. The decentralized autonomous organization (DAO) focuses on raising funds for human life extension research.

Pharmaceutical giant Pfizer Ventures, venture fund Shine Capital, investment group L1 Digital, decentralized science organizations BeakerDAO and Spaceship DAO are the major investors in the latest funding round for VitaDAO.

Tyler Golato of the decentralized biotech protocol Molecule founded VitaDAO in 2021 to fund longevity research. Moreover, the organization mentions that it has a community of over 9,000 enthusiasts, researchers, and contributors. It spent over $3.5 million on projects in 2022, researching ageing diseases, repairing age-related body damage, and cellular biology.

A native VITA governs the VitaDAO organization token. Additionally, holders can vote on which projects to support, with a group of stewards, helping execute these proposals. The group intends to expand beyond physical locations and is considering “a potential future sovereignty network.”

Pfizer, according to VitaDAO, is the first pharmaceutical company to vote on DAO proposals and participate in VitaDAO project incubation and commercialization.

Latest fund to be used for Longevity Research Projects

The latest fund raiser will fund longevity research projects and the development of VitaDAO’s first biotech startup. It will be announced in the first quarter of 2023. Furthermore, the company intends to invest more in the commercialization and licensing of its non-fungible token (NFT) intellectual property (IP) through its partnership with Molecule.

Several VitaDAO-funded projects have advanced to the next stage of development. This would include clinical trials with Mantis Photonics to diagnose Alzheimer’s disease using retinal imaging.

Moreover, crypto enthusiasts have long been interested in longevity science and the prevention of human ageing. In December 2021, Coinbase CEO Brian Armstrong founded NewLimit, a company to cure ageing. Moreover, former Ripple CTO and current Stellar co-founder Jed McCaleb founded the Astera Institute to fund longevity research.

Disclaimer: AMBCrypto's content is meant to be informational in nature and should not be interpreted as investment advice. Trading, buying or selling cryptocurrencies should be considered a high-risk investment and every reader is advised to do their own research before making any decisions.

Saman Waris

Editor

Saman Waris works as a Senior News Editor at AMBCrypto. She has always been fascinated by how the tides of finance and technology shape communities across demographics. Cryptocurrencies are of particular interest to Saman, with much of her writing centered around understanding how ideas like Momentum and Greater Fool theories apply to altcoins, specifically, memecoins.

Related Articles

AMBCrypto
Facebook X Instagram Youtube Linkedin

AMBCrypto was founded in 2018 with a mission to simplify and bring the latest blockchain and cryptocurrency news to our readers. We have quickly grown into the digital news source for an emerging generation of cryptocurrency enthusiasts, reaching more than a million readers on a monthly basis, across the globe.